Bainey KR, Welsh RC, Connolly SJ, et al. - Given that reduction in the primary major adverse cardiovascular event (MACE) outcome of cardiovascular death, myocardial infarction, or stroke, as well as, mortality, was achieved with dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily vs aspirin 100 mg once daily in patients with chronic coronary syndromes or peripheral arterial disease in the COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies), so, researchers undertook a prespecified subgroup analysis from COMPASS to determine if this is true in patients with a history of percutaneous coronary intervention (PCI). They focused on the results of patients with chronic coronary syndrome with or without a previous PCI managed with DPI vs aspirin alone. Findings revealed that consistent decreases in MACE and mortality were brought about by DPI, vs aspirin, but with increased major bleeding with or without prior PCI. Experts found the impacts on MACE as well as mortality were consistent, regardless of time since last PCI, among those with prior PCI 1 year and beyond.